Brind.

Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.

5 reports, 3 independent Updated Oct 12

Gone quiet

Reports: 5
Developments: 2
Repetition: 60%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.

Who's involved

What this event is mainly about

Syndax Pharmaceuticals Incyte

How it developed

Newest first. Tap a step to see who reported it.

Oct 6NIKTIMVO receives expedited approval in Brazil; companies secure worldwide co-development license.1 source
- intelligencer.ca
Aug 5Syndax reports collaboration revenue from Niktimvo sales.1 source
- GlobeNewswire

Keep exploring

The entities involved

Syndax Pharmaceuticals
business

Nothing else this week.
Incyte
American pharmaceutical company
- Prelude Therapeutics developed a selective KAT6A degrader, and Incyte may exercise an option for financing.22:22
- Incyte is scheduled to present research data at the European Society for Medical Oncology (ESMO) congress in Madrid.Mon 02:35

Related events

Shares of Syndax Pharmaceuticals were traded on the Nasdaq stock exchange on August 12, 2026.Aug 12

Coverage

Newest first; wire copies grouped

Oct 6intelligencer.ca
Oct 1manilatimes.net
Aug 5GlobeNewswireSyndax Reports Second Quarter 2025 Financial Results and Provides Business Update – $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo

2 more outlets ran the same wire story

Oct 12econotimes.com
Oct 6manilatimes.net